Straits Times Index
3,306.08 -16.00 (-0.48%) Nikkei
39,134.79 +96.63 (+0.25%) Hang Seng
18,193.80 -173.15 (-0.94%) FTSE 100
8,239.05 +10.57 (+0.13%) Bitcoin USD
67,513.33 -1,896.12 (-2.73%) CMC Crypto 200
1,398.44 -43.20 (-3.00%)
Tiziana Life Sciences Ltd (0RP.F)
| Previous close | 0.9050 |
| Open | 0.8850 |
| Bid | 0.8850 x N/A |
| Ask | 0.9700 x N/A |
| Day's range | 0.8850 - 0.8850 |
| 52-week range | 0.0620 - 0.8850 |
| Volume | |
| Avg. volume | 0 |
| Market cap | 92.095M |
| Beta (5Y monthly) | 0.23 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.1600 |
| Earnings date | 28 May 2024 - 12 Jun 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
GlobeNewswireTiziana Life Sciences Announces Six-Month Qualitative Improvement in Neuroimaging in 80% of Multiple Sclerosis Patients Receiving Intranasal Foralumab
Qualitative improvements in PET imaging seen in 80% of non-active Secondary Progressive Multiple Sclerosis (na-SPMS) Expanded Access patients receiving intranasal foralumab for at least 6-months.FDA Allowance for an additional 20 Patients to be enrolled in the intranasal foralumab Multiple Sclerosis Expanded Access Program will allow further data collection and analysis.Applied for FDA Orphan Drug Designation of foralumab for na-SPMS NEW YORK, June 06, 2024 (GLOBE NEWSWIRE) -- Tiziana Life Scien
- GlobeNewswire
Tiziana Life Sciences Submits Grant Application to ALS Association to Fund Clinical Trial of Intranasal Foralumab
NEW YORK, June 04, 2024 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, today announced it has been honored with an invitation to apply for a prestigious grant from the ALS Association head by James Berry, MD, MPH and Suma Babu, MBBS, MS, the Director and Co-Director of the N
- GlobeNewswire
Tiziana Life Sciences Scientific Board Chairman to Receive Prestigious Award for Multiple Sclerosis Research
NEW YORK, May 30, 2024 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies via novel routes of drug delivery, today announced that Howard L. Weiner, M.D., Chairman of Tiziana’s Scientific Advisory Board and co-director of the Ann Romney Center for Neurologic Diseases at Brigham and Women's Hospital, a founding member of Mass General Brigham healthcare system, is being honored with
